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ABSTRACT	  
	  
THE	  INFLUENCE	  OF	  REGIONAL	  HEALTH	  SYSTEM	  CHARACTERISTICS	  ON	  THE	  
MANAGEMENT	  OF	  GLIOBLASTOMA	  MULTIFORME.	  Dhruv	  Khullar,	  Sanjay	  Aneja,	  James	  
B.	  Yu.	  Department	  of	  Therapeutic	  Radiology,	  Yale	  University,	  School	  of	  Medicine,	  New	  
Haven,	  CT.	  	  
	  
Despite	  a	  known	  optimal	  treatment	  protocol	  for	  the	  management	  of	  glioblastoma	  
multiforme	  (GBM),	  many	  patients	  fail	  to	  receive	  complete	  surgical	  resection	  or	  post-­‐
operative	  radiation	  therapy	  (PORT).	  The	  underlying	  reasons	  behind	  this	  disparity	  are	  
unclear.	  We	  hypothesize	  that	  regional	  health	  system	  resources	  influence	  the	  surgical	  
management	  and	  PORT	  in	  patients	  with	  GBM.	  	  
	   Surgical	  intervention,	  PORT	  receipt,	  and	  patient	  data	  for	  patients	  diagnosed	  with	  
GBM	  from	  2004	  to	  2008	  were	  obtained	  from	  the	  NCI	  Surveillance,	  Epidemiology,	  and	  
End	  Results	  (SEER)	  database	  and	  combined	  with	  the	  health	  system	  data	  from	  the	  Area	  
Resource	  File.	  Health	  system	  characteristics	  studied	  included	  radiation	  oncologist	  
density,	  neurosurgeon	  density,	  primary	  care	  provider	  (PCP)	  density,	  general	  radiation	  
therapy	  (RT)	  and/or	  medical	  oncology	  (MO)	  equipped	  hospital	  density,	  and	  median	  
household	  income.	  The	  geographic	  units	  of	  analysis	  were	  NCI-­‐defined	  Health	  Service	  
Areas	  (HSA)	  within	  the	  SEER	  registry.	  Four	  logistic	  models	  were	  constructed	  to	  test	  the	  
effect	  of	  health	  system	  characteristics	  on	  surgical	  treatment	  choice	  and	  PORT	  receipt.	  	  	  
	   Of	  the	  8,337	  patients	  in	  our	  sample	  that	  were	  diagnosed	  with	  GBM,	  71.45%	  
received	  PORT.	  We	  found	  that	  younger,	  married	  patients	  in	  HSAs	  with	  higher	  median	  
incomes	  were	  significantly	  more	  likely	  to	  receive	  both	  gross	  total	  resection	  (p	  <	  .001,	  p	  
<	  .001,	  p	  =	  0.002)	  and	  PORT	  (p	  <	  .001,	  p	  <	  .001,	  p	  =	  .008).	  For	  every	  $10,000	  increase	  in	  
the	  median	  income	  of	  a	  HSA,	  a	  patient’s	  likelihood	  of	  receiving	  gross	  resection	  and	  
PORT	  increased	  by	  7%	  and	  6.3%,	  respectively.	  The	  density	  of	  primary	  care	  providers	  
	   iii	  
and	  radiation	  oncology	  equipped	  hospitals	  were	  also	  significant	  predictors	  of	  PORT	  
receipt	  (p	  =	  .024,	  p	  =	  .002).	  Patient	  race,	  radiation	  oncologist,	  and	  neurosurgeon	  
densities	  were	  not	  associated	  with	  likelihood	  to	  receive	  PORT	  
	   Our	  findings	  suggest	  that	  regional	  variations	  in	  neuro-­‐oncology	  services	  and	  
income	  may	  have	  impact	  on	  GBM	  management.	  The	  presence	  of	  hospitals	  with	  oncology	  
services	  within	  an	  HSA	  was	  more	  predictive	  of	  PORT	  receipt	  than	  the	  density	  of	  
radiation	  oncologists	  and	  neurosurgeons	  themselves,	  suggesting	  that	  hospital-­‐level	  
infrastructure	  is	  needed	  to	  optimize	  care	  of	  GBM,	  independent	  of	  physician	  staffing	  
levels.	  Policies	  aimed	  at	  narrowing	  disparities	  in	  treatment	  may	  need	  to	  focus	  on	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  author.	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  follows:	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  system	  
	   characteristics	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  the	  surgical	  management	  and	  receipt	  of	  post	  operative	  
	   radiation	  therapy	  for	  glioblastoma	  multiforme.	  J	  Neurooncol.	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   1	  
INTRODUCTION	  
The	  Physician	  Workforce	  
Understanding	  the	  composition	  of	  the	  physician	  workforce	  and	  the	  organization	  of	  
health	  systems	  is	  becoming	  increasingly	  important	  as	  the	  United	  States	  continues	  to	  
reform	  its	  health	  care	  system	  in	  pursuit	  of	  higher	  quality,	  broader	  access,	  and	  greater	  
efficiency.	  Though	  concerns	  about	  an	  inadequate	  physician	  supply	  have	  been	  noted	  for	  
decades,1	  the	  passage	  of	  the	  Affordable	  Care	  Act	  (ACA)—and	  the	  subsequent	  influx	  of	  
millions	  of	  Americans	  into	  the	  health	  care	  system—have	  brought	  these	  issues	  to	  the	  
forefront	  of	  recent	  health	  policy	  debates.2,3	  By	  some	  estimates,	  the	  current	  physician	  
shortage	  is	  expected	  to	  swell	  to	  130,000	  physicians	  by	  2025,	  including	  a	  quadrupling	  of	  
the	  specialist	  shortage.4,5	  While	  the	  ACA’s	  insurance	  expansion	  may	  exacerbate	  the	  
predicted	  physician	  shortage,	  population	  growth	  and	  aging	  are	  thought	  to	  be	  the	  
primary	  drivers	  of	  increased	  health	  care	  utilization.6	  The	  recently	  established	  National	  
Healthcare	  Workforce	  Commission	  is	  charged	  with	  monitoring	  the	  supply	  and	  
distribution	  of	  physicians.	  
	  
Already,	  low-­‐income	  individuals	  in	  the	  United	  States	  report	  greater	  difficulty	  accessing	  
health	  care	  than	  their	  counterparts	  in	  other	  industrialized	  countries.7	  The	  ACA’s	  
coverage	  expansion	  may	  help	  alleviate	  these	  difficulties,	  but	  it	  can	  only	  do	  so	  if	  there	  is	  
an	  adequate	  physician	  supply	  to	  meet	  greater	  demand.	  Some	  have	  argued	  that	  greater	  
dependence	  of	  mid-­‐level	  providers	  offers	  a	  cost-­‐effective	  avenue	  to	  fill	  the	  physician	  
shortage,	  especially	  in	  primary	  care.8,9	  	  
	  
	   2	  
Over	  the	  past	  decade,	  there	  has	  been	  a	  fifteen-­‐fold	  increase	  in	  Medicare	  patients	  
receiving	  care	  from	  nurse	  practitioners.	  Not	  surprisingly,	  states	  with	  less	  restrictive	  
regulations	  have	  seen	  the	  greatest	  increase	  in	  the	  use	  of	  nurse	  practitioners	  as	  primary	  
care	  providers.10	  Nurse	  practitioners	  and	  physician	  assistants	  may	  also	  have	  an	  
increasingly	  important	  role	  to	  play	  in	  the	  delivery	  of	  cancer	  care,	  given	  the	  increasing	  
complexity	  of	  oncologic	  care	  and	  projected	  increase	  in	  demand	  for	  oncology	  
services.11,12	  But	  the	  ability	  of	  mid-­‐level	  providers	  to	  address	  physician	  shortages	  is	  not	  
without	  controversy,	  and	  physicians	  and	  mid-­‐level	  providers	  have	  been	  found	  to	  
disagree	  significantly	  on	  their	  respective	  roles	  in	  the	  delivery	  of	  medical	  care.13	  	  
	  
Geographic	  Maldistribution	  of	  Physicians	  
While	  some	  are	  concerned	  about	  an	  absolute	  shortage	  of	  physicians,	  others	  contend	  
that	  a	  geographic	  maldistribution	  of	  providers	  is	  an	  equally	  important	  threat	  to	  access	  
and	  quality.14,15	  Recent	  analyses	  suggest	  that	  states	  with	  more	  physicians	  tend	  to	  have	  
better	  health	  care	  access	  and	  higher	  quality.16	  This	  may	  be	  especially	  true	  for	  primary	  
care	  physicians.	  The	  primary	  care	  physician	  supply	  has	  been	  associated	  with	  a	  host	  of	  
better	  health	  outcomes	  including	  improvements	  in	  all-­‐cause	  mortality,	  cancer,	  heart	  
disease,	  stroke,	  infant	  mortality,	  and	  life	  expectancy.17,18	  	  	  
	  
Simply	  increasing	  the	  overall	  supply	  of	  physicians	  may	  not	  address	  the	  regional	  
differences	  in	  physician	  supply,	  as	  physicians	  tend	  to	  settle	  in	  areas	  that	  already	  have	  a	  
relatively	  high	  density	  of	  providers.	  One	  study	  found	  that	  while	  there	  was	  a	  50%	  
increase	  in	  physicians	  per-­‐capita	  from	  1979	  to	  1999,	  for	  every	  four	  physicians	  that	  
	   3	  
settled	  in	  a	  high-­‐supply	  region,	  only	  one	  settled	  in	  a	  low-­‐supply	  region.18,19	  Another	  
study	  found	  that	  while	  the	  number	  of	  cardiologists	  has	  increased	  modestly	  since	  the	  
1990s,	  a	  significant	  maldistribution	  of	  the	  workforce	  persists,	  with	  60%	  of	  the	  elderly	  
having	  access	  to	  less	  than	  40%	  of	  cardiologists.	  Rural	  and	  low	  socioeconomically	  
disadvantaged	  areas	  are	  more	  likely	  to	  have	  lower	  concentrations	  of	  cardiologists.20	  
	   	  
This	  geographic	  maldistribution	  may	  be	  even	  more	  pronounced	  for	  smaller	  specialties,	  
with	  rural	  areas	  experiencing	  the	  lowest	  physician-­‐to-­‐population	  ratios.21	  For	  example,	  
while	  the	  radiation	  oncology	  workforce	  increased	  24%	  from	  1995	  to	  2007,	  there	  is	  
considerable	  variability	  in	  the	  density	  of	  providers	  across	  the	  country.	  Areas	  with	  
higher	  education,	  higher	  income,	  and	  higher	  minority	  populations	  seem	  to	  have	  higher	  
radiation	  oncologist-­‐to-­‐population	  ratios.22	  Ensuring	  patients	  have	  adequate	  access	  to	  
the	  services	  they	  need	  in	  the	  coming	  years	  will	  require	  policies	  aimed	  not	  only	  at	  
increasing	  the	  absolute	  number	  of	  physicians,	  but	  also	  addressing	  how	  those	  physicians	  
are	  distributed.	  	  
	  
Physician	  Density	  and	  Health	  Outcomes	  
There	  is	  growing	  evidence	  that	  health	  system	  characteristics	  like	  the	  distribution	  of	  
providers	  can	  influence	  the	  type	  and	  quality	  of	  medical	  care	  delivered.	  A	  recent	  analysis	  
found	  that	  as	  compared	  to	  Medicare	  beneficiaries	  living	  in	  regions	  with	  low	  primary	  
care	  physician	  density,	  those	  in	  higher	  density	  areas	  had	  lower	  mortality	  rates	  and	  
fewer	  hospitalizations.23	  Medicare	  patients	  in	  poor	  or	  fair	  health	  are	  almost	  twice	  as	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likely	  to	  have	  a	  preventable	  hospitalization	  if	  they	  live	  in	  an	  area	  with	  a	  primary	  care	  
shortage.24	  	  
	  
These	  effects	  may	  be	  especially	  pronounced	  for	  patients	  with	  chronic	  illnesses	  who	  
require	  frequent	  contact	  with	  the	  health	  system	  to	  appropriately	  manage	  their	  disease.	  
One	  recent	  study	  found	  that	  heart	  failure	  patients	  residing	  in	  rural,	  low	  socioeconomic,	  
and	  low	  physician	  density	  regions	  are	  less	  likely	  to	  receive	  early	  follow-­‐up	  after	  being	  
discharged	  from	  the	  hospital,	  significantly	  increasing	  their	  risk	  for	  readmission.25	  
Another	  study	  focused	  on	  hospitalizations	  for	  inflammatory	  bowel	  disease	  (IBD).	  It	  
found	  that	  while	  the	  rate	  of	  IBD	  hospitalizations	  was	  similar	  in	  high	  physician	  density	  
and	  low	  physician	  density	  counties,	  patients	  in	  high	  density	  counties	  presented	  to	  the	  
hospital	  with	  less	  complicated	  disease	  and	  ultimately	  had	  lower	  hospitalization	  
charges.26	  	  
	  
Health	  System	  Characteristics	  and	  Oncologic	  Care	  
The	  influence	  of	  regional	  health	  systems	  and	  physician	  workforce	  on	  cancer	  care	  
specifically	  is	  also	  increasingly	  being	  recognized.	  Physician	  density	  has	  been	  shown	  to	  
influence	  health	  outcomes	  in	  a	  variety	  of	  diseases,27,28	  and	  evidence	  suggests	  that	  the	  
density	  of	  primary	  care	  physicians	  may	  be	  particularly	  important	  for	  reducing	  cancer	  
mortality	  rates.29	  Significant	  and	  persistent	  geographic	  maldistributions	  of	  oncologic	  
specialists	  and	  health	  resources	  have	  also	  been	  associated	  with	  variations	  in	  treatment	  
patterns,	  as	  well	  as	  clinical	  outcomes,	  and	  highlight	  a	  potential	  driver	  of	  cancer-­‐related	  
disparities.22,30	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The	  effect	  of	  physician	  supply	  on	  cancer	  care	  is	  often	  nuanced	  and	  complex.	  For	  
example,	  one	  recent	  study	  found	  that	  the	  presence	  of	  at	  least	  one	  urologist	  per	  county	  is	  
associated	  with	  reduced	  mortality	  for	  urologic	  cancers.	  However,	  a	  density	  greater	  than	  
two	  urologists	  per	  100,000	  people	  yields	  no	  additional	  mortality	  benefit.31	  Higher	  
densities	  of	  gastroenterologists	  reduced	  delays	  in	  diagnosis	  of	  gastric	  cancer	  in	  rural	  
areas,	  but	  additional	  gastroenterologists	  had	  no	  effect	  in	  urban	  areas,	  where	  the	  density	  
of	  physicians	  is	  already	  relatively	  high.32	  Similarly,	  higher	  gastroenterologist	  density	  is	  
associated	  with	  a	  14-­‐17%	  reduction	  in	  late-­‐stage	  colorectal	  cancer	  in	  non-­‐metropolitan	  
counties.33	  Women	  living	  in	  areas	  with	  more	  mammography	  facilities	  and	  an	  adequate	  
supply	  of	  primary	  care	  providers	  are	  more	  likely	  to	  adhere	  to	  mammography	  screening	  
guidelines.34	  	  	  
	  
Evidence	  from	  other	  countries	  also	  supports	  the	  hypothesis	  that	  local	  health	  resources	  
and	  physician	  density	  have	  an	  important	  impact	  on	  cancer	  screening	  and	  treatment.	  In	  
Canada	  for	  example,	  women	  with	  breast	  cancer	  who	  reside	  in	  areas	  with	  higher	  
OB/GYN	  and	  primary	  care	  densities	  have	  higher	  survival	  rates	  at	  5	  years.35	  In	  Germany,	  
increases	  in	  physician	  supply	  have	  been	  associated	  with	  small	  reductions	  in	  avoidable	  
deaths	  for	  cancers	  of	  the	  breast,	  colon,	  rectum,	  and	  anus.36	  Researchers	  in	  France	  found	  
that	  women	  living	  in	  areas	  with	  low	  practitioner	  density	  were	  at	  higher	  risk	  for	  delayed	  
cervical	  cancer	  screening.37,38	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In	  the	  United	  States,	  the	  recent	  health	  reform	  legislation	  has	  placed	  a	  new	  focus	  on	  
assessing	  the	  adequacy	  of	  the	  supply	  and	  geographic	  distribution	  of	  the	  physician	  
workforce.39	  At	  a	  time	  when	  the	  health	  care	  system	  is	  in	  flux,	  a	  deeper	  understanding	  of	  
how	  the	  distribution	  of	  specialists	  and	  oncology	  centers	  influences	  cancer	  treatment	  
may	  be	  helpful	  for	  developing	  policies	  that	  promote	  better	  patient	  outcomes.	  Our	  study	  
investigates	  the	  influence	  of	  regional	  health	  system	  resources	  on	  the	  treatment	  of	  a	  
particularly	  aggressive	  type	  of	  cancer,	  glioblastoma	  multiforme	  (GBM),	  by	  examining	  its	  
surgical	  management	  and	  the	  receipt	  of	  post-­‐operative	  radiation	  therapy	  (PORT)	  across	  
the	  United	  States.	  	  
	  
Disparities	  in	  Management	  of	  Glioblastoma	  Multiforme	  
GBM	  is	  the	  most	  common	  brain	  tumor	  in	  adults	  and	  continues	  to	  carry	  a	  very	  poor	  
prognosis	  with	  a	  median	  survival	  of	  approximately	  one	  year.40	  It	  accounts	  for	  
approximately	  25%	  of	  primary	  CNS	  tumors	  in	  adults,	  and	  the	  annual	  incidence	  is	  5	  per	  
100,000.41	  Risk	  factors	  include	  male	  gender,	  age	  greater	  than	  50,	  history	  of	  receiving	  
radiotherapy,	  having	  a	  low-­‐grade	  brain	  tumor,	  genetic	  disorders	  such	  as	  
neurofibromatosis,	  and	  Caucasian,	  Asian,	  or	  Hispanic	  ethnicity.42	  Patients	  often	  present	  
with	  new	  onset	  headaches	  or	  seizures,	  progressive	  cognitive	  dysfunction,	  behavioral	  
and	  personality	  changes,	  and	  neurological	  deficits	  depending	  on	  location	  of	  the	  tumor.	  
	  
GBM	  offer	  appears	  as	  a	  ring-­‐enhancing	  lesion	  when	  viewed	  on	  MRI,	  but	  definitive	  
diagnosis	  requires	  biopsy	  and	  pathologic	  confirmation.	  A	  number	  of	  diagnostic	  and	  
prognostic	  molecular	  tests	  are	  routinely	  performed,	  including	  testing	  for	  chromosome	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1p	  and	  19q	  deletions,43	  MGMT	  promoter	  methylation,44	  and	  IDH1/IDH2	  enzyme	  
mutations.45	  	  
	  
While	  GBM	  carries	  a	  poor	  prognosis,	  several	  factors	  are	  associated	  with	  improved	  
survival	  including	  lower	  tumor	  grade,	  younger	  age,	  and	  better	  Karnofsky	  performance	  
status.40	  Patients	  with	  frontal	  lobe	  tumors	  have	  longer	  median	  survival	  after	  surgery	  
compared	  to	  those	  with	  temporal	  or	  parietal	  lobe	  tumors.46	  The	  current	  standard	  of	  
treatment	  for	  GBM	  includes	  maximal	  surgical	  resection	  followed	  by	  post-­‐operative	  
radiation	  therapy	  (PORT)	  in	  combination	  with	  chemotherapy.47	  Some	  authors	  have	  
found	  the	  extent	  of	  surgical	  resection	  to	  be	  the	  most	  important	  prognostic	  factor	  in	  
patients	  diagnosed	  with	  GBM.48	  Gross	  total	  resection—removal	  of	  all	  visibly	  abnormal	  
tissue	  seen	  on	  MRI	  or	  intraoperatively—should	  be	  attempted	  when	  possible,	  and	  tumor	  
biopsy	  or	  partial	  resection	  should	  be	  considered	  only	  when	  total	  resection	  is	  
determined	  to	  be	  unsafe	  or	  unfeasible.48,49	  	  
	  
Partial	  resection	  seems	  to	  improve	  outcomes	  as	  compared	  to	  biopsy	  only,	  suggesting	  a	  
survival	  benefit	  of	  tumor	  debulking.	  One	  recent	  study	  found	  significant	  survival	  benefit	  
with	  subtotal	  resections	  as	  low	  as	  78%	  of	  tumor.50	  Regardless	  of	  the	  extent	  of	  initial	  
resection,	  gross	  total	  resection	  should	  be	  attempted	  on	  recurrence,	  as	  it	  has	  been	  found	  
to	  overcome	  the	  effect	  of	  initial	  subtotal	  resection	  and	  maximize	  survival.51	  	  
	  
Because	  microscopic	  residual	  disease	  remains	  even	  after	  removal	  of	  the	  visible	  tumor,	  
surgical	  resection	  should	  be	  followed	  by	  PORT	  administration.	  Randomized	  controlled	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trials	  have	  found	  a	  doubling	  of	  survival	  in	  some	  patients	  who	  receive	  PORT.52,53	  
Regardless	  of	  extent	  of	  tumor	  resection,	  patients	  receiving	  adequate	  doses	  of	  PORT	  
have	  longer	  median	  survival,54	  and	  radiotherapy	  has	  been	  shown	  to	  improve	  survival	  in	  
both	  young	  and	  elderly	  GBM	  patients.55	  This	  regimen	  may	  increase	  functional	  status	  
and	  survival	  even	  in	  patients	  with	  relatively	  low	  Karnofsky	  Performance	  Scores.56	  
	  
More	  recently,	  studies	  have	  shown	  that	  temozolamide	  administered	  in	  conjunction	  with	  
PORT	  can	  improve	  survival.57	  Authors	  have	  found	  an	  increase	  in	  median	  survival	  of	  2.5	  
months	  with	  limited	  adverse	  effects	  in	  patients	  receiving	  temozolamide	  in	  addition	  to	  
radiotherapy,	  as	  compared	  to	  radiotherapy	  alone.	  Recent	  trials	  continue	  to	  provide	  
further	  support	  for	  use	  of	  temozolamide	  to	  improve	  overall	  and	  progression	  free	  
survival.58	  While	  the	  cost	  of	  adjuvant	  temozolamide	  is	  substantial,	  several	  authors	  have	  
concluded	  that	  it	  is	  a	  cost-­‐effective	  addition	  to	  GBM	  management,	  especially	  if	  the	  
generic	  drug	  is	  used,	  with	  quality-­‐adjusted	  life	  year	  gains	  comparable	  to	  other	  first-­‐line	  
chemotherapeutic	  agents.59,60	  However,	  others	  argue	  that	  the	  addition	  of	  temozolamide	  
in	  resource-­‐poor	  health	  settings	  is	  not	  cost-­‐effective,	  and	  should	  be	  used	  preferentially	  
in	  subgroups	  with	  more	  favorable	  prognostic	  factors.61	  	  
	  
Regional	  health	  system	  resources	  have	  been	  associated	  with	  variations	  in	  outcomes	  in	  a	  
number	  of	  cancers,	  but	  these	  factors	  have	  not	  been	  well-­‐described	  in	  the	  treatment	  of	  
GBM.	  Despite	  an	  established	  optimal	  treatment	  protocol,	  some	  patients	  with	  GBM	  fail	  to	  
receive	  complete	  surgical	  resection	  or	  PORT,	  highlighting	  a	  concerning	  gap	  in	  
treatment.40	  The	  underlying	  reasons	  behind	  the	  disparity	  in	  treatment	  are	  poorly	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understood,	  but	  are	  particularly	  troubling	  given	  the	  high	  mortality	  rate	  associated	  with	  
GBM.	  In	  the	  United	  States,	  the	  density	  of	  neurosurgeons	  and	  radiation	  oncologist	  
specialists	  varies	  significantly	  by	  county.22	  Workforce	  discrepancies	  persist	  when	  
examining	  density	  of	  hospitals	  providing	  oncologic	  services,	  thus	  leaving	  segments	  of	  
the	  population	  without	  access	  to	  the	  specialized	  care	  they	  need.	  These	  variations	  may	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SPECIFIC	  AIMS	  
1. To	  understand	  whether	  patient	  and	  health	  system	  characteristics	  are	  associated	  
with	  variations	  in	  the	  surgical	  management	  of	  patients	  with	  GBM.	  	  
2. To	  understand	  whether	  patient	  and	  health	  system	  characteristics	  are	  associated	  
with	  receipt	  of	  post-­‐operative	  radiation	  therapy	  for	  patients	  with	  GBM.	  	  
3. To	  examine	  regional	  variations	  in	  the	  density	  of	  neuro-­‐oncologic	  providers	  and	  
hospitals	  (i.e.,	  neurosurgeons,	  radiation	  oncologists,	  general	  oncologists)	  across	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METHODS	  
Data	  Sources	  and	  Study	  Sample	  
There	  were	  two	  primary	  data	  sources	  utilized	  in	  this	  study.	  Clinical	  data	  was	  derived	  
from	  the	  National	  Cancer	  Institute’s	  Surveillance,	  Epidemiology,	  and	  End	  Results	  
(SEER)	  public-­‐use	  database.	  The	  SEER	  dataset	  began	  in	  1973	  and	  collects	  information	  
on	  incident	  cancer	  cases,	  now	  covering	  approximately	  26%	  of	  the	  United	  States	  from	  17	  
cancer	  registries.22,62	  The	  dataset	  provides	  clinical	  information	  including	  patient	  age,	  
gender,	  race,	  marital	  status,	  histology,	  primary	  tumor	  site,	  morphology,	  stage	  at	  
diagnosis,	  initial	  treatment,	  and	  overall	  survival.	  	  
	  
The	  study	  sample	  included	  patients	  within	  the	  SEER	  dataset	  aged	  18	  years	  or	  older	  
diagnosed	  with	  GBM	  (International	  Classification	  of	  Diseases	  for	  Oncology,	  Version	  3	  
histology	  codes	  9440–9442)	  between	  the	  years	  2004	  and	  2008.	  Patient	  data	  of	  interest	  
included	  patient	  age,	  race	  and	  marital	  status.	  Clinical	  data	  studied	  included	  type	  of	  
surgical	  intervention	  and	  whether	  the	  patient	  received	  post-­‐operative	  external-­‐beam	  
radiation	  therapy.	  
	  
Health	  system	  data	  was	  obtained	  from	  the	  2007	  edition	  of	  the	  Area	  Resource	  File	  (ARF).	  
Published	  by	  the	  Health	  Resources	  and	  Services	  Administration	  of	  the	  United	  States	  
Department	  of	  Health	  and	  Human	  Services,	  the	  ARF	  is	  a	  collection	  of	  data	  from	  over	  50	  
sources,	  including	  the	  American	  Medical	  Association,	  American	  Hospitalization	  
Association,	  US	  Census,	  and	  National	  Center	  for	  US	  Health	  Statistics.63	  The	  ARF	  
aggregates	  information	  concerning	  the	  health	  care	  professionals,	  health	  care	  facilities,	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and	  population	  for	  each	  county	  in	  the	  United	  States.	  Health	  system	  characteristics	  
studied	  included	  number	  of	  population,	  radiation	  oncologists,	  neurosurgeons,	  primary	  
care	  physicians,	  radiation	  therapy-­‐equipped	  hospitals,	  general	  oncology	  equipped	  
hospitals,	  and	  median	  household	  income	  within	  a	  county	  from	  2004	  to	  2008.	  	  
	  
Construction	  of	  Variables	  
All	  statistical	  analyses	  were	  carried	  out	  with	  the	  help	  of	  Sanjay	  Aneja,	  MD.	  The	  
geographic	  units	  of	  analysis	  were	  the	  154	  Health	  Service	  Areas	  (HSAs)	  within	  the	  SEER	  
dataset	  as	  defined	  by	  the	  National	  Center	  for	  Health	  Statistics	  and	  National	  Cancer	  
Institute.	  HSAs	  are	  defined	  as	  a	  single	  county	  or	  group	  of	  contiguous	  counties	  that	  
remain	  self-­‐contained	  with	  respect	  to	  hospital	  care.	  HSAs	  were	  chosen	  as	  the	  unit	  of	  
analysis	  because	  they	  best	  represent	  geographic	  access	  to	  healthcare	  within	  a	  region.	  
County	  level	  data	  from	  the	  ARF	  was	  aggregated	  to	  HSAs	  using	  simple	  summation	  for	  
physician	  and	  population	  variables	  and	  population	  weighted	  sums	  descriptive	  variables.	  
Physician	  and	  hospital	  densities	  were	  calculated	  at	  5-­‐year	  population	  averages	  per	  
100,000	  residents.	  To	  isolate	  patients	  who	  were	  candidates	  for	  curative	  treatment	  and	  
to	  prevent	  immortal	  time	  bias,	  patients	  who	  did	  not	  receive	  any	  surgical	  intervention	  or	  
those	  who	  died	  within	  6	  months	  of	  diagnosis	  were	  excluded	  from	  the	  analysis.64	  
Additionally,	  patients	  who	  received	  radiation	  other	  than	  external-­‐beam	  radiation	  
therapy	  were	  excluded	  from	  the	  analysis.	  	  
	  
Statistical	  Analysis	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To	  visually	  evaluate	  the	  relative	  distribution	  of	  neuro-­‐oncologic	  resources	  across	  the	  
United	  States,	  physician	  densities	  and	  hospital	  densities	  were	  mapped	  using	  to	  
corresponding	  HSAs	  using	  the	  geographical	  information	  system	  ArcGIS	  Version	  9.2	  
(Environmental	  Systems	  Research	  Institute,	  Inc.,	  Redlands,	  CA).	  	  	  	  
	  
A	  total	  of	  four	  logistic	  models	  were	  constructed	  to	  test	  the	  effect	  of	  health	  system	  
characteristics	  on	  surgical	  treatment	  choice	  and	  receipt	  of	  post-­‐operative	  radiation	  
therapy	  (PORT).	  Three	  logistic	  models	  were	  built	  to	  test	  the	  influence	  of	  regional	  health	  
care	  systems	  on	  whether	  patients	  underwent	  gross	  total	  resection,	  partial	  resection,	  or	  
only	  biopsy.	  Because	  we	  assumed	  that	  radiation	  therapy	  services	  were	  unlikely	  to	  be	  
related	  to	  initial	  surgical	  treatment	  choice,	  density	  of	  radiation	  oncologists	  and	  
radiation	  therapy	  equipped	  hospitals	  were	  excluded	  from	  the	  surgery	  logistic	  models.	  
To	  test	  the	  factors	  associated	  with	  the	  receipt	  of	  PORT	  a	  fourth	  logistic	  model	  was	  build,	  
which	  included	  radiation	  oncologist	  and	  radiation	  therapy	  equipped	  hospital	  density.	  
Statistical	  significance	  was	  determined	  at	  p<.05.	  Statistical	  analysis	  was	  conducted	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RESULTS	  
In	  total,	  8,337	  patients	  within	  the	  SEER	  dataset	  were	  diagnosed	  with	  GBM	  from	  2004	  to	  
2008.	  Of	  these,	  2,346	  (28.2%)	  were	  excluded	  because	  they	  received	  only	  radiation	  
therapy	  (1,207	  patients)	  or	  no	  curative	  treatment	  (1,139	  patients).	  Our	  final	  study	  
cohort	  included	  5,991	  patients	  with	  a	  mean	  age	  of	  61	  years	  ranging	  from	  ages	  18	  to	  
95.1	  years.	  68.1%	  of	  the	  study	  sample	  was	  married	  and	  90.6%	  was	  white.	  	  
	  
Patients	  were	  more	  likely	  to	  receive	  gross	  total	  resection	  and	  PORT	  (38.6%)	  than	  any	  
other	  treatment	  regimen.	  However,	  a	  substantial	  proportion	  of	  patients	  received	  partial	  
resection	  and	  PORT	  (29.8%)	  or	  only	  biopsy	  and	  PORT	  (15.5%).	  A	  smaller	  number	  of	  
patients	  received	  gross	  resection	  (7.7%),	  partial	  resection	  (8.2%),	  or	  biopsy	  only	  
(4.8%)	  without	  PORT.	  	  
	  
We	  found	  that	  the	  density	  of	  neurosurgical,	  radiation	  therapy,	  and	  general	  oncology	  
services	  varied	  geographically	  among	  different	  HSAs	  within	  the	  SEER	  registry.	  
Moreover,	  we	  found	  a	  geographic	  maldistribution	  of	  both	  specialists	  and	  hospitals	  
across	  all	  HSAs	  within	  the	  United	  States	  (Figure	  1	  and	  2).	  Among	  the	  HSAs	  studied	  we	  
found	  significant	  variability	  in	  the	  density	  of	  radiation	  oncology	  hospitals	  (median	  =	  
2.52	  per	  100,000	  residents,	  range	  =	  0	  to	  4.09),	  general	  oncology	  hospitals	  (median	  =	  
0.537	  per	  100,000	  residents,	  range	  =	  0	  to	  14.3),	  neurosurgeons	  (median	  =	  1.7	  per	  
100,000	  residents,	  range	  =	  0	  to	  5.13),	  and	  radiation	  oncology	  specialists	  (median	  =	  1.42	  
per	  100,000	  residents,	  range	  =	  0	  to	  3.55).	  The	  median	  household	  income	  of	  HSAs	  
analyzed	  was	  found	  to	  be	  $56,800	  with	  a	  range	  of	  $24,770	  to	  $90,800.	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Predictors	  of	  gross	  resection	  are	  listed	  in	  Table	  1.	  Younger,	  married	  patients	  who	  lived	  
in	  HSAs	  with	  higher	  median	  incomes	  were	  significantly	  more	  likely	  to	  receive	  gross	  
total	  resection	  (p	  <	  .001,	  p	  <	  .001,	  p	  =	  0.002).	  For	  every	  $10,000	  increase	  in	  the	  median	  
income	  of	  a	  HSA,	  a	  patient’s	  likelihood	  of	  receiving	  gross	  resection	  increased	  by	  7%.	  
Importantly,	  patient	  race,	  density	  of	  neurosurgeons,	  and	  density	  of	  oncology	  
departments	  were	  not	  associated	  with	  complete	  resection.	  	  
	  






















1.00	   0.04	   0.911	   0.91	   1.08	  
White	  Race	   1.08	   0.10	   0.430	   0.90	   1.30	  
Married	   1.91	   0.11	   <0.001	   1.71	   2.13	  
Age	   0.95	   0.01	   <0.001	   0.94	   0.95	  
Median	  
Household	  
Income	  of	  HSA	  





1.07	   0.04	   0.580	   1.00	   1.16	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Figure	  1:	  Geographic	  Distribution	  of	  Neurosurgeons	  and	  Radiation	  Oncologists	  
Across	  the	  United	  States.	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Figure	  2:	  Geographic	  Distribution	  of	  General	  Oncology	  and	  Radiation	  Therapy	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Unmarried	  patients	  from	  HSAs	  with	  lower	  median	  incomes	  were	  associated	  with	  
receiving	  biopsy	  only	  (p	  =	  .004,	  p	  <	  .001).	  As	  the	  median	  income	  of	  a	  patient’s	  HSA	  
decreases	  by	  $10,000,	  a	  patient	  becomes	  15%	  more	  likely	  to	  receive	  biopsy	  only	  for	  
treatment	  of	  GBM.	  Unmarried	  patients	  were	  18%	  more	  likely	  to	  receive	  biopsy	  only.	  
Patient	  age,	  race,	  density	  of	  neurosurgeons,	  and	  density	  of	  oncology	  departments	  were	  
not	  associated	  with	  likelihood	  of	  biopsy.	  These	  results	  are	  presented	  in	  Table	  2.	  Partial	  
tumor	  resection	  was	  not	  associated	  with	  any	  patient,	  population,	  or	  health	  system	  
characteristics	  analyzed	  in	  our	  model	  (Table	  3).	  	  
	  










1.03	   0.04	   0.352	   0.96	   1.11	  
White	  Race	   0.94	   0.10	   0.607	   0.76	   1.17	  
Married	   0.82	   0.06	   0.004	   0.72	   0.94	  
Age	   1.00	   0.01	   0.147	   0.99	   1.01	  
Median	  Household	  
Income	  of	  HSA	  




0.94	   0.04	   0.148	   0.86	   1.02	  
	  
	  










1.00	   0.03	   0.991	   0.94	   1.06	  
White	  Race	   0.87	   0.08	   0.141	   0.73	   1.05	  
Married	   1.01	   0.06	   0.921	   0.89	   1.13	  
Age	   1.00	   0.01	   0.257	   0.99	   1.01	  
Median	  Household	   1.04	   0.01	   0.113	   0.99	   1.09	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1.02	   0.04	   0.562	   0.95	   1.09	  
	  
Overall,	  of	  the	  8,337	  patients	  diagnosed	  with	  GBM	  analyzed	  in	  our	  initial	  sample,	  
71.45%	  received	  PORT.	  The	  predictors	  of	  PORT	  receipt	  are	  listed	  in	  Table	  4.	  As	  with	  
extent	  of	  surgical	  resection,	  patient	  race	  was	  not	  associated	  with	  PORT	  receipt,	  but	  
patient	  age	  and	  marital	  status	  were	  predictors	  of	  PORT	  receipt.	  Younger,	  married	  
patients	  were	  more	  likely	  to	  receive	  PORT	  after	  surgery	  (p	  <	  .001,	  p	  <	  .001).	  Once	  again,	  
the	  relative	  affluence	  of	  an	  HSA	  was	  significantly	  associated	  with	  a	  patient’s	  likelihood	  
of	  receiving	  treatment	  (p	  =	  .008).	  Every	  $10,000	  increase	  in	  HSA	  median	  income	  
increases	  the	  likelihood	  of	  PORT	  receipt	  by	  6.3%.	  	  
	  
Table	  4:	  Predictors	  of	  PORT	  Receipt	  
	  
Predictors	  of	  PORT	  
Receipt	   Odds	  Ratio	   Error	   p	  
95	  %	  Confidence	  
Interval	  
Radiation	  Oncologist	  
Density	   1.07	   0.07	   0.258	   0.95	   1.22	  
Primary	  Care	  Physician	  
Density	   1.01	   0.01	   0.024	   1.00	   1.01	  
Neurosurgeon	  Density	   1.00	   0.04	   0.911	   0.91	   1.08	  
White	  Race	   1.08	   0.10	   0.426	   0.90	   1.30	  
Married	   1.91	   0.11	   <.001	   1.71	   2.13	  
Radiation	  Oncology	  
Equipped	  Hospital	  Density	   1.43	   0.14	   0.002	   1.18	   1.74	  
Age	   0.95	   0.01	   <.001	   0.94	   0.95	  
Median	  Household	  Income	  
of	  HSA	   1.06	   0.01	   0.028	   1.00	   1.12	  
Medical	  Oncology	  Equipped	  
Hospital	  Density	   1.07	   0.04	   0.058	   1.00	   1.16	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There	  were	  also	  a	  number	  of	  health	  system	  factors	  associated	  with	  PORT	  receipt.	  The	  
density	  of	  primary	  care	  providers	  (PCPs)	  and	  density	  of	  radiation	  oncology	  equipped	  
hospitals	  were	  significant	  predictors	  of	  PORT	  receipt	  (p	  =	  .024,	  p	  =	  .002).	  Importantly,	  
while	  the	  density	  of	  oncology-­‐equipped	  hospitals	  predicts	  PORT	  receipt,	  the	  density	  of	  
individual	  radiation	  oncologists	  and	  neurosurgeons	  were	  not	  associated	  with	  likelihood	  
of	  receiving	  PORT.	  Overall,	  marital	  status	  and	  density	  of	  radiation	  oncology	  equipped	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DISCUSSION	  
Recent	  evidence	  has	  shown	  improvement	  in	  the	  outcomes	  of	  patients	  diagnosed	  with	  
GBM.	  However,	  this	  improvement	  is	  seen	  only	  in	  patients	  who	  receive	  the	  
recommended	  multidisciplinary	  treatment.65	  Our	  findings	  confirm	  a	  geographic	  
maldistribution	  of	  radiation	  therapy	  and	  general	  oncology	  services	  that	  leaves	  
significant	  portions	  of	  the	  population	  without	  ready	  access	  to	  radiation	  therapy.22	  We	  
found	  that	  patient	  age,	  marital	  status,	  and	  median	  income	  of	  HSA	  are	  significant	  
predictors	  of	  surgical	  resection	  and	  PORT	  receipt.	  The	  density	  of	  radiation	  oncology	  
departments	  was	  also	  a	  predictor	  of	  PORT	  receipt.	  Our	  findings	  suggest	  that	  hospital	  
infrastructure	  may	  be	  more	  closely	  associated	  with	  variations	  in	  GBM	  management	  
than	  is	  physician	  supply.	  Regional	  variations	  in	  socioeconomic	  status	  are	  also	  
associated	  with	  discrepancies	  in	  GBM	  treatment.	  	  
	  
Extent	  of	  Surgical	  Resection	  
Some	  authors	  have	  found	  the	  extent	  of	  surgical	  resection	  to	  be	  the	  most	  important	  
prognostic	  factor	  of	  GBM	  mortality.	  Both	  overall	  and	  event-­‐free	  survival	  rates	  are	  
substantially	  higher	  in	  patients	  who	  receive	  total	  tumor	  resection	  versus	  those	  who	  
receive	  non-­‐total	  resection.48	  A	  number	  of	  tumor	  characteristics	  including	  size,	  location,	  
stage,	  and	  histology	  influence	  a	  surgeon’s	  ability	  to	  achieve	  complete	  tumor	  
resection.49,66	  	  
	  
Given	  that	  the	  extent	  of	  tumor	  removal	  is	  a	  strong	  predictor	  of	  survival,	  maximal	  
resection	  should	  be	  attempted	  whenever	  possible,	  and	  tumor	  biopsy	  or	  partial	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resection	  should	  be	  considered	  only	  when	  total	  resection	  is	  determined	  to	  be	  unsafe	  or	  
unfeasible.48,49	  Our	  study	  corroborates	  previous	  findings	  that	  patient	  age	  and	  marital	  
status	  predict	  likelihood	  of	  gross	  resection.67	  Furthermore,	  we	  found	  that	  every	  
$10,000	  increase	  in	  HSA	  median	  household	  income	  increases	  a	  patient’s	  chances	  of	  
achieving	  gross	  resection	  by	  7%.	  	  
	  
One	  possible	  reason	  for	  the	  socioeconomic	  disparity	  of	  patients	  undergoing	  gross	  total	  
resection	  may	  be	  that	  those	  living	  in	  HSAs	  with	  higher	  median	  incomes	  have	  better	  
access	  to	  hospital	  resources	  and	  improved	  coordination	  of	  care.	  Research	  has	  long	  
demonstrated	  an	  association	  between	  low	  SES,	  limited	  access	  to	  health	  care	  services,	  
and	  poorer	  health	  outcomes.68-­‐70	  Low	  SES	  patients	  are	  more	  likely	  to	  use	  acute	  hospital	  
care	  and	  less	  likely	  to	  use	  primary	  care	  services	  for	  a	  number	  of	  reasons,	  including	  
perceiving	  hospital	  care	  as	  higher	  quality,	  more	  accessible,	  and	  less	  expensive.71	  
Disparities	  in	  access	  may	  result	  from	  provider	  behavior	  as	  well.	  A	  recent	  study	  found	  
that	  even	  in	  the	  absence	  of	  significant	  economic	  incentives,	  office	  staff	  are	  more	  likely	  to	  
schedule	  high	  SES	  patients	  for	  an	  appointment,	  and	  that	  patients	  presenting	  themselves	  
as	  high	  SES	  have	  preferential	  access	  to	  primary	  care	  services.72	  	  
	  
Another	  potential	  explanation	  for	  the	  SES	  disparity	  we	  found	  is	  that	  individuals	  living	  in	  
HSAs	  with	  higher	  median	  incomes	  present	  earlier	  in	  the	  disease	  course,	  and	  thus	  have	  
smaller,	  more	  resectable	  tumors.	  Once	  again,	  this	  explanation	  is	  supported	  by	  research	  
in	  other	  types	  of	  cancer.	  Recent	  studies	  examining	  patients	  with	  breast,	  prostate,	  
colorectal,	  and	  testicular	  cancer	  suggest	  that	  low	  SES	  patients	  are	  diagnosed	  at	  a	  later	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stage	  and	  may	  receive	  a	  less	  aggressive	  treatment	  course.73-­‐75	  Low	  SES	  prostate	  and	  
breast	  cancer	  patients	  tend	  to	  have	  higher	  incidence,	  and	  worse	  mortality	  and	  survival	  
rates	  than	  their	  more	  affluent	  counterparts.76,77	  Another	  study	  found	  that	  low	  SES	  was	  
significantly	  associated	  with	  advanced	  tumor	  stage	  and	  reduced	  likelihood	  to	  pursue	  
curative	  treatment,	  even	  when	  insurance	  coverage	  and	  access	  to	  health	  care	  were	  
identical	  across	  groups.78	  Other	  work	  has	  found	  that	  lower	  patient	  education	  level	  is	  
strongly	  associated	  with	  higher	  cancer	  death	  rates.	  For	  example,	  black	  men	  with	  fewer	  
than	  12	  years	  of	  schooling	  had	  prostate	  cancer	  death	  rates	  more	  than	  twice	  that	  of	  
black	  men	  with	  more	  schooling.79	  	  
	  
Interestingly,	  in	  our	  study	  neither	  the	  density	  of	  neurosurgeons,	  nor	  the	  density	  of	  
general	  oncology	  equipped	  hospitals	  was	  associated	  with	  likelihood	  of	  total	  resection.	  
This	  suggests	  other	  factors	  associated	  with	  socioeconomic	  status	  may	  play	  a	  larger	  role	  
in	  extent	  of	  surgical	  resection	  than	  number	  of	  physicians	  and	  hospitals.	  	  For	  example,	  it	  
may	  be	  that	  surgeons	  in	  higher	  SES	  areas	  are	  more	  determined	  to	  obtain	  full	  resection,	  
or	  patients	  from	  those	  areas	  are	  more	  ardent	  about	  pursuing	  one.	  There	  is	  some	  
evidence	  to	  suggest	  that	  black	  and	  white	  patients	  are	  treated	  by	  different	  subgroups	  of	  
physicians,80	  and	  that	  physicians	  may	  communicate	  differently	  with	  different	  subsets	  of	  
patients.81	  Furthermore,	  differences	  in	  the	  hospitals	  in	  which	  minorities	  receive	  their	  
care	  may	  contribute	  to	  the	  type	  and	  quality	  of	  treatment	  they	  receive,	  and	  ultimately	  
result	  in	  poorer	  health	  outcomes.	  For	  example,	  minorities	  are	  more	  likely	  to	  undergo	  
coronary	  artery	  bypass	  graft	  (CABG)	  surgeries	  in	  low-­‐volume	  centers	  and	  performed	  by	  
surgeons	  with	  higher	  risk-­‐adjusted	  mortality	  rates.82	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It	  is	  also	  possible	  that	  patients	  from	  lower	  SES	  areas	  have	  more	  comorbidities,	  and	  thus	  
are	  less	  likely	  to	  pursue	  or	  be	  eligible	  for	  aggressive	  treatment.	  Evidence	  suggests	  that	  
elderly	  GBM	  patients	  with	  more	  comorbidities	  are	  significantly	  less	  likely	  than	  their	  
healthier	  counterparts	  to	  receive	  radiotherapy	  or	  chemotherapy.83	  More	  generally,	  low	  
SES	  patients	  diagnosed	  with	  breast,	  lung,	  and	  colorectal	  cancer	  are	  more	  likely	  than	  
high	  SES	  patients	  to	  have	  at	  least	  one	  other	  chronic	  condition.84,85	  One	  recent	  study	  
found	  that	  low	  SES	  patients	  had	  a	  50%	  increased	  risk	  of	  serious	  comorbidity—such	  as	  
cardiovascular	  disease,	  cerebrovascular	  disease,	  chronic	  obstructive	  pulmonary	  disease,	  
or	  diabetes	  mellitus—than	  high	  SES	  patients,	  which	  partly	  explains	  disparities	  in	  one-­‐
year	  survival	  rates.86	  	  
	  
The	  burden	  of	  comorbid	  disease	  in	  cancer	  patients	  may	  be	  increasing	  because	  of	  an	  
aging	  and	  increasingly	  obese	  population.	  In	  a	  recent	  study	  of	  colorectal	  cancer	  patients,	  
rates	  of	  comorbidity	  increased	  from	  47%	  to	  62%	  from	  1995	  to	  2010,	  and	  multiple	  
comorbidity	  rates	  from	  20%	  to	  37%,	  with	  hypertension	  and	  cardiovascular	  disease	  
being	  the	  most	  prevalent.	  84	  These	  findings	  underscore	  the	  growing	  importance	  of	  
optimal	  management	  of	  cancer	  patients	  with	  multiple	  comorbid	  conditions,	  especially	  
for	  low	  SES	  patient	  populations.	  	  	  
	  
As	  compared	  to	  biopsy	  only,	  partial	  resection	  seems	  to	  improve	  outcomes,	  suggesting	  a	  
survival	  benefit	  of	  tumor	  debulking.48	  We	  found	  that	  partial	  tumor	  resection	  was	  not	  
associated	  with	  any	  predictors	  in	  our	  model,	  suggesting	  that	  other	  factors	  such	  as	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tumor	  characteristics	  play	  a	  more	  important	  role	  in	  limited	  resection	  than	  do	  social	  and	  
health	  system	  factors.	  As	  compared	  with	  complete	  resections,	  limited	  resections	  may	  be	  
relatively	  unplanned	  occurrences	  influenced	  largely	  by	  intraoperative	  events	  or	  
findings.	  	  
	  
Factors	  Predicting	  PORT	  Receipt	  
Surgical	  resection	  should	  ideally	  be	  followed	  by	  PORT	  administration,	  as	  some	  
randomized	  controlled	  trials	  have	  found	  substantial	  survival	  benefits	  in	  patients	  who	  
receive	  PORT	  without	  significant	  adverse	  effects	  or	  reductions	  in	  quality	  of	  life	  or	  
cognition.52,53	  Recently,	  survival	  rates	  have	  been	  found	  to	  improve	  further	  with	  the	  
administration	  of	  concurrent	  temozolomide,	  though	  some	  trials	  have	  found	  higher	  risk	  
of	  cognitive	  deterioration.57,87	  	  
	  
Our	  study	  corroborates	  previous	  findings	  that	  PORT	  administration	  does	  not	  take	  place	  
in	  a	  significant	  proportion	  of	  GBM	  patients,88,89	  with	  increasing	  patient	  age	  and	  
unmarried	  status	  being	  associated	  with	  a	  lower	  likelihood	  of	  PORT.	  	  Other	  recent	  
analyses	  have	  found	  that	  younger	  GBM	  patients	  (age	  <	  70	  years)	  have	  seen	  greater	  
improvements	  in	  overall	  survival,	  potentially	  because	  of	  this	  disparity	  in	  PORT	  
receipt.90	  As	  such,	  increased	  attention	  to	  and	  counseling	  for	  older,	  unmarried	  
individuals	  may	  be	  warranted.	  	  
	  
Unique	  to	  our	  study	  is	  the	  finding	  that	  the	  median	  household	  income	  of	  a	  patient’s	  HSA	  
significantly	  influences	  the	  likelihood	  of	  PORT	  receipt.	  We	  found	  that	  the	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administration	  of	  PORT	  follows	  a	  similar	  trend	  to	  surgical	  resection	  in	  that	  every	  
$10,000	  increase	  in	  HSA	  median	  income	  increases	  a	  patient’s	  likelihood	  of	  receiving	  
PORT	  by	  approximately	  6%.	  
	  
The	  association	  of	  lower	  income	  and	  worse	  health	  outcomes	  is	  well	  documented	  in	  a	  
number	  of	  oncologic	  and	  non-­‐oncologic	  diseases,74,91-­‐94	  and	  new	  standards	  of	  care	  seem	  
to	  disseminate	  more	  rapidly	  in	  high	  SES	  areas.	  For	  example,	  a	  recent	  analysis	  found	  that	  
the	  examination	  of	  12	  or	  more	  lymph	  nodes	  in	  patients	  with	  colon	  cancer—a	  new	  
standard	  of	  care—is	  more	  likely	  in	  high	  SES	  patients.92	  Patients	  in	  the	  highest	  SES	  
quintile	  had	  a	  30%	  increased	  odds	  of	  12-­‐node	  dissection	  as	  compared	  to	  patients	  in	  the	  
lowest	  quintile.	  Similar	  results	  can	  be	  found	  in	  other	  areas.	  Men	  with	  testicular	  germ	  
cell	  tumors	  living	  in	  low	  SES	  regions	  are	  more	  likely	  to	  present	  with	  advanced	  disease	  
and	  have	  higher	  rates	  of	  mortality.74	  Patients	  from	  poorer	  areas	  are	  less	  likely	  to	  
receive	  chemotherapy	  for	  melanoma	  than	  their	  more	  affluent	  counterparts.91	  However,	  
the	  association	  of	  SES	  and	  management	  is	  a	  new	  finding	  with	  respect	  to	  patients	  with	  
GBM.	  	  
	  
The	  Complex	  Role	  of	  Provider	  Density	  
Our	  findings	  indicate	  that	  it	  may	  not	  be	  the	  density	  of	  individual	  radiation	  oncologists,	  
but	  rather	  the	  prevalence	  of	  radiation	  oncology	  centers	  that	  influences	  PORT	  receipt,	  
suggesting	  a	  dominant	  role	  of	  hospital-­‐level	  infrastructure	  over	  individual	  providers	  for	  
addressing	  disparities	  in	  GBM	  management.	  While	  the	  prevalence	  of	  specialists	  such	  
radiation	  oncologists	  and	  neurosurgeons	  was	  not	  associated	  with	  PORT	  receipt,	  the	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density	  of	  PCPs	  was.	  The	  reason	  for	  this	  effect	  is	  unclear.	  It	  may	  be	  that	  PCP	  density	  is	  a	  
proxy	  for	  a	  robust	  health	  system	  and	  effective	  coordination	  of	  care.	  Indeed,	  prior	  
research	  suggest	  a	  number	  of	  salutary	  effects	  of	  health	  systems	  with	  strong	  primary	  
care	  foundations,	  including	  lower	  health	  care	  costs,	  fewer	  hospital	  days,	  and	  better	  
continuity	  of	  care.18	  Our	  finding	  further	  substantiates	  the	  importance	  of	  a	  region’s	  
health	  infrastructure	  as	  a	  significant	  predictor	  of	  PORT	  receipt	  in	  patients	  with	  GBM.	  	  
	  
As	  we	  continue	  to	  search	  for	  ways	  to	  improve	  treatment	  of	  patients	  with	  GBM	  and	  other	  
cancers,	  we	  would	  do	  well	  to	  keep	  in	  mind	  the	  influence	  of	  PCPs	  on	  early	  detection	  and	  
comprehensive	  management.	  The	  ACA’s	  emphasis	  on	  incentivizing	  integrated	  health	  
care	  delivery	  systems	  may	  prove	  helpful	  in	  addressing	  some	  of	  the	  disparities	  
stemming	  from	  fragmented	  care.	  The	  recent	  formation	  of	  hundreds	  of	  Accountable	  Care	  
Organizations	  (ACOs)—provider	  networks	  responsible	  for	  the	  care	  of	  an	  attributed	  
population	  of	  patients—may	  increase	  care	  coordination	  and	  improve	  timely	  diagnosis	  
and	  treatment	  of	  cancers	  including	  GBM.	  Initial	  results	  from	  the	  evaluation	  of	  
Medicare’s	  Pioneer	  ACOs	  have	  been	  mixed,	  but	  some	  organizations	  have	  seen	  
significant	  quality	  and	  efficiency	  improvements.95	  	  
	  
Similarly,	  increasing	  interest	  in	  primary	  care-­‐led	  organizations	  like	  Patient-­‐Centered	  
Medical	  Homes	  (PCMHs)	  with	  value-­‐based	  reimbursement	  systems	  may	  help	  improve	  
access	  and	  care	  coordination.	  More	  recently,	  Oncology	  PMCHs	  (OPCMHs)	  have	  been	  
proposed	  as	  a	  model	  to	  integrate	  care,	  emphasize	  accountability,	  and	  enhance	  
communication	  among	  providers	  and	  cancer	  patients.96	  In	  2013,	  AETNA	  launched	  the	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first	  OPCMH	  in	  Pennsylvania,	  where	  patients	  can	  receive	  oncologic	  and	  non-­‐oncologic	  
care,	  in	  an	  effort	  to	  reduce	  cancer-­‐related	  complications,	  emergency	  room	  visits,	  and	  
hospital	  readmissions.97	  The	  efficacy	  of	  these	  health	  care	  delivery	  models	  for	  improving	  
cancer	  management	  should	  continue	  to	  be	  evaluated	  in	  the	  coming	  years.	  
	  
Patient	  Race	  and	  Management	  of	  GBM	  
Patient	  race	  has	  been	  associated	  with	  variations	  in	  care	  and	  outcomes	  in	  a	  variety	  of	  
cancers.98-­‐101	  However,	  in	  our	  study,	  race	  was	  not	  associated	  with	  variations	  in	  surgical	  
management	  or	  receipt	  of	  radiation	  therapy	  for	  patients	  with	  GBM.	  In	  this	  sense,	  the	  
management	  of	  GBM	  may	  be	  a	  model	  for	  other	  cancers,	  particularly	  those	  in	  which	  
race-­‐based	  disparity	  in	  treatment	  has	  been	  shown.102-­‐104	  	  
	  
However,	  this	  encouraging	  finding	  may	  be	  related	  to	  the	  relatively	  grave	  nature	  of	  GBM,	  
and	  it	  is	  important	  to	  recognize	  the	  significant	  historical	  and	  pathophysiological	  
differences	  between	  GBM	  and	  other	  malignancies.	  For	  example,	  while	  many	  breast	  and	  
prostate	  cancer	  patients	  receive	  treatment	  in	  smaller	  free-­‐standing	  centers,	  almost	  all	  
GBM	  patients	  receive	  care	  in	  large	  academic	  centers.	  Furthermore,	  there	  is	  less	  
controversy	  with	  regard	  to	  optimal	  screening	  and	  management	  of	  GBM	  patients	  as	  
compared	  to	  other	  cancers.	  Lastly,	  the	  natural	  history	  of	  GBM	  predicts	  uniformly	  poor	  
survival,	  while	  greater	  prognostic	  variation	  exists	  in	  other	  types	  of	  cancer.	  	  
	  
Limitations	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Our	  study	  has	  several	  limitations.	  Because	  the	  SEER	  dataset	  comprises	  only	  26%	  of	  the	  
US	  population,	  we	  must	  be	  cautious	  about	  generalizing	  findings	  to	  the	  country	  as	  a	  
whole.	  That	  said,	  the	  SEER	  dataset	  has	  a	  relatively	  diverse	  geographic	  representation	  of	  
health	  systems	  across	  the	  United	  States	  and	  includes	  registries	  from	  both	  rural	  and	  
urban	  regions	  in	  many	  states.	  Another	  limitation	  of	  the	  SEER	  dataset	  is	  that	  it	  does	  not	  
provide	  specific	  information	  regarding	  radiation	  therapy	  technique,	  dosage,	  and	  volume.	  
However,	  this	  likely	  has	  a	  greater	  effect	  on	  survival	  analysis	  than	  on	  receipt	  of	  radiation	  
therapy,	  the	  main	  variable	  assessed	  in	  this	  study.	  Finally,	  recent	  evidence	  has	  found	  the	  
SEER	  dataset	  to	  underestimate	  the	  receipt	  of	  radiation	  therapy	  following	  breast-­‐
conserving	  surgery.105	  There	  has,	  however,	  been	  no	  similar	  evidence	  to	  suggest	  under-­‐
ascertainment	  for	  PORT	  in	  the	  setting	  of	  GBM.	  	  
	  
The	  ARF	  also	  has	  several	  limitations	  that	  should	  be	  noted.	  First,	  the	  physician	  location	  
data	  from	  the	  ARF	  is	  aggregated	  from	  the	  American	  Medical	  Association	  (AMA)	  
Physician	  Masterfile.	  Because	  the	  AMA	  Masterfile	  does	  not	  account	  for	  physicians	  with	  
multiple	  practices	  in	  different	  regions,	  it	  is	  possible	  that	  we	  overestimate	  the	  
geographic	  clustering	  of	  radiation	  oncologists	  and	  neurosurgeons.	  However,	  while	  
these	  specialists	  may	  practice	  in	  multiple	  locations,	  it	  is	  likely	  that	  their	  practices	  fall	  
within	  the	  same	  HSA.	  Second,	  the	  ARF	  does	  not	  contain	  information	  regarding	  
freestanding	  radiation	  therapy	  centers	  within	  different	  health	  systems.	  Nonetheless,	  
our	  analysis	  suggests	  a	  relative	  maldistribution	  of	  radiation	  therapy	  services	  across	  the	  
United	  States.	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Finally,	  our	  study	  does	  not	  examine	  other	  barriers	  to	  care	  such	  as	  lack	  of	  health	  
insurance	  and	  whether	  radiation	  oncology	  centers	  accept	  Medicaid	  payment	  for	  their	  
services.	  Evidence	  suggests	  that,	  depending	  on	  the	  specialty,	  30-­‐50%	  of	  office-­‐based	  
physicians	  do	  not	  accept	  Medicaid,	  and	  that	  often,	  waiting	  times	  for	  Medicaid	  patients	  
are	  significantly	  longer	  than	  for	  the	  privately	  insured.106,107	  These	  unexamined	  factors	  
may	  also	  contribute	  to	  the	  disparities	  highlighted	  in	  this	  paper,	  and	  will	  be	  important	  to	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CONCLUSION	  
In	  conclusion,	  meaningful	  discrepancies	  exist	  for	  GBM	  patients	  with	  regard	  to	  receipt	  of	  
two	  important	  predictors	  of	  survival:	  gross	  resection	  and	  PORT.	  Our	  findings	  confirm	  
that	  patient	  factors	  such	  as	  age	  and	  marital	  status	  influence	  a	  patient’s	  likelihood	  of	  
receiving	  full	  surgical	  resection	  and	  PORT.	  Furthermore,	  our	  findings	  suggest	  that	  a	  
geographic	  maldistribution	  of	  oncology	  services	  and	  SES	  discrepancies	  in	  HSAs	  may	  
have	  serious	  clinical	  implications	  for	  patients	  with	  GBM.	  Thus,	  policies	  aimed	  at	  
narrowing	  disparities	  in	  treatment	  may	  need	  to	  focus	  on	  improving	  coordination	  of	  
care	  and	  addressing	  gaps	  in	  oncology	  department	  density.	  Further	  studies	  are	  
warranted	  to	  better	  understand	  the	  influence	  of	  health	  system	  resources	  on	  the	  extent	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